Septerna FY2025 EPS Forecast Lifted by Cantor Fitzgerald

Septerna, Inc. (NASDAQ:SEPN) – Equities research analysts at Cantor Fitzgerald boosted their FY2025 EPS estimates for Septerna in a report released on Monday, May 19th. Cantor Fitzgerald analyst J. Schimmer now anticipates that the company will earn ($0.14) per share for the year, up from their previous forecast of ($2.01). Cantor Fitzgerald has a “Overweight” rating and a $25.00 price objective on the stock. The consensus estimate for Septerna’s current full-year earnings is ($7.11) per share.

Separately, Wells Fargo & Company upped their price target on Septerna from $11.00 to $18.00 and gave the stock an “equal weight” rating in a research note on Friday, May 16th.

Septerna Price Performance

Shares of Septerna stock opened at $9.42 on Wednesday. Septerna has a 1 year low of $4.17 and a 1 year high of $28.99. The company’s fifty day moving average is $6.55 and its two-hundred day moving average is $14.05.

Septerna (NASDAQ:SEPN) last announced its quarterly earnings results on Thursday, May 15th. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.11). The company had revenue of $0.22 million for the quarter.

Institutional Trading of Septerna

Institutional investors have recently added to or reduced their stakes in the business. RA Capital Management L.P. purchased a new position in Septerna in the 4th quarter worth approximately $160,205,000. TRV GP V LLC purchased a new stake in Septerna during the 4th quarter worth $142,337,000. BVF Inc. IL lifted its holdings in Septerna by 79.3% in the 1st quarter. BVF Inc. IL now owns 4,396,124 shares of the company’s stock worth $25,454,000 after buying an additional 1,944,100 shares in the last quarter. TRV GP VI LLC increased its position in shares of Septerna by 33.6% during the first quarter. TRV GP VI LLC now owns 4,211,659 shares of the company’s stock worth $24,386,000 after acquiring an additional 1,059,203 shares during the last quarter. Finally, Driehaus Capital Management LLC grew its position in shares of Septerna by 20.6% during the first quarter. Driehaus Capital Management LLC now owns 3,122,608 shares of the company’s stock worth $18,080,000 after buying an additional 533,055 shares in the last quarter.

Insider Buying and Selling

In related news, CFO Gil M. Labrucherie acquired 5,000 shares of the business’s stock in a transaction dated Friday, February 21st. The shares were acquired at an average cost of $5.85 per share, for a total transaction of $29,250.00. Following the acquisition, the chief financial officer now directly owns 30,000 shares in the company, valued at approximately $175,500. The trade was a 20.00% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Alan Ezekowitz purchased 41,355 shares of the firm’s stock in a transaction on Thursday, March 6th. The stock was bought at an average price of $6.00 per share, for a total transaction of $248,130.00. Following the acquisition, the director now owns 104,101 shares in the company, valued at $624,606. The trade was a 65.91% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders purchased 63,846 shares of company stock worth $381,815. 4.30% of the stock is owned by corporate insiders.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.